$ACN

Susquehanna Lifts Accenture Price Target to $210 From $153

Susquehanna raised its price target for Accenture to $210 from $153. Separately, Goldman Sachs increased its target to $260 from $230. Accenture's stock has seen recent gains.

Original reporting
Published Oct 1, 2026, 5:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 5:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACN
Bullish
high confidence
Mentioned
$ACN
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ACNBullishHigh
01

Why it matters

The new $210 target signals a 37% upside from the prior $153 level, prompting traders to consider buying on dips.

02

Market read

A fresh, higher price target can drive immediate buying interest and affect sector peers.

03

What to watch

Potential macro slowdown could limit demand for consulting services.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Accenture (ACN) is a leading global consulting and professional services firm. Analyst upgrades often influence short-term price action.

Company-level read

Ticker impact

$ACNBullishHigh confidence
Context

Susquehanna raised Accenture's price target to $210 from $153, a fresh analyst upgrade.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

Analyst target lifts are a direct catalyst that can move the stock in the short term.

Market effects

May lift other consulting peers as analysts reassess sector outlook.

U.S. market sentiment for tech services could improve.

Limited to U.S. equities; no broader macro impact.

Counterpoint

Target raises can be premature; price may already reflect expectations.

Key entities

  • Susquehanna

    Equity research house that issued the price target lift.

  • Accenture

    Global consulting and professional services firm.

Related articles

$ACNMed

Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more

Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.